Harvard Apparatus Regenerative Technology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Harvard Apparatus Regenerative Technology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 27, 2020 |
| FY2017 | Dec 31, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Dec 31, 2016 | $28.0K | Apr 3, 2018 |
| FY2017 | Sep 30, 2016 | $26.0K | Apr 3, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $704.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $430.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $103.0K | Mar 31, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Apr 3, 2018 |
| FY2017 | Dec 31, 2016 | ($31.0K) | Apr 3, 2018 |
| FY2017 | Sep 30, 2016 | $13.0K | Apr 3, 2018 |
| FY2017 | Jun 30, 2016 | ($16.0K) | Apr 3, 2018 |
| FY2017 | Mar 31, 2016 | $0 | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | ($76.0K) | Mar 17, 2017 |
| FY2016 | Sep 30, 2015 | $19.0K | Mar 17, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.87M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($7.73M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($8.95M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.07M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($7.98M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($4.87M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($8.33M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($7.53M) | Mar 27, 2020 |
| FY2017 | Dec 31, 2017 | ($1.23M) | Apr 3, 2018 |
| FY2017 | Sep 30, 2017 | ($3.24M) | Apr 3, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.92M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($7.73M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($8.99M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.15M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($8.64M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($5.33M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($8.87M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($7.84M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($11.47M) | Mar 29, 2019 |
| FY2016 | Dec 31, 2016 | ($3.58M) | Mar 17, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.65M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.31M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.74M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.59M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.07M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.85M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $3.92M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $7.59M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $7.60M | Apr 3, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $4.41M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $7.04M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.26M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.02M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $3.93M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $3.88M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.49M | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $6.89M | Mar 17, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.83M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($4.85M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($6.94M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.11M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.63M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($4.04M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($6.06M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($7.64M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($11.01M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($9.06M) | Apr 3, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $11.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.0K | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | $0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $7.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $129.0K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $131.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $136.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $302.0K | Apr 3, 2018 |
| FY2016 | Dec 31, 2015 | $176.0K | Mar 17, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.68M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.44M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.40M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.87M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.08M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.99M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $2.63M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.05M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.55M | Apr 3, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.62M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.22M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $968.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.41M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.90M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $951.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $903.0K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $662.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.62M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.78M | Apr 3, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.22M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.65M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | ($3.19M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($3.03M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.13M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $1.09M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.97M | Apr 13, 2021 |
| FY2019 | Dec 31, 2017 | $3.42M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.77M | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($106.56M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($99.69M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($91.96M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($83.01M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($76.94M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($68.96M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($64.10M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($55.76M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($48.23M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($36.32M) | Apr 3, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.49M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $432.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.24M | Mar 28, 2024 |
| FY2017 | Dec 31, 2017 | $4.04M | Apr 3, 2018 |
| FY2017 | Dec 31, 2016 | $2.94M | Apr 3, 2018 |
| FY2017 | Dec 31, 2015 | $7.46M | Apr 3, 2018 |
| FY2016 | Dec 31, 2014 | $5.27M | Mar 17, 2017 |
| FY2015 | Dec 31, 2013 | $14.01M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $0 | Mar 27, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17.58M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 15.92M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 13.95M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 12.17M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 10.76M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 9.39M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 8.16M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | 5.67M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 2.51M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 855,448 | Apr 3, 2018 |